Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearItem 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On December 8, 2016, the Board of Directors of Synergy Pharmaceuticals Inc. (the “Company”) approved a resolution amending its bylaws by adding Section 6.5 to Article VI as follows:
“SECTION 6.5 Issue of Certificates; Book-Entry System.
The Board of Directors may make such additional rules and regulations, not inconsistent with the Bylaws or the Certificate of Incorporation, as it may deem expedient concerning the issue, transfer and registration of certificates for shares of stock of the corporation. Further, the corporation may participate in one or more systems under which certificates for shares of stock are replaced by electronic book-entry to such rules, terms and conditions as the Board of Directors may approve and subject to applicable law, notwithstanding any provisions to the contrary set forth in this Article.”
Item 8.01 Other Events.
On December 9, 2016, Company issued a press release announcing positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, an investigational once-daily orally-administered compound, in 1,135 adult patients with irritable bowel syndrome with constipation (IBS-C).
The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Synergy Pharmaceuticals Inc. Press Release dated December 9, 2016.
About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Recent Trading Information
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) closed its last trading session down -0.28 at 4.94 with 5,460,684 shares trading hands.
